login
login

Europe Daily Bulletin No. 12834

18 November 2021
Contents Publication in full By article 20 / 29
EU RESPONSE TO COVID-19 / Health
European Medicines Agency could authorise use of Novavax’s Covid-19 vaccine within weeks
Brussels, 17/11/2021 (Agence Europe)

The European Medicines Agency (EMA) announced on Wednesday 17 November that it had received a conditional marketing authorisation application for the Covid-19 vaccine Nuvaxovid (NVX-CoV2373) developed by the US laboratory Novavax.

The Agency has already examined a large amount of data on this vaccine, the rolling review of which started in February 2021.

As a result, the review of the application for authorisation “will proceed under an accelerated timeline, and an opinion on the...

Contents

SECTORAL POLICIES
EXTERNAL ACTION
SOCIAL - YOUHT
INSTITUTIONAL
EU RESPONSE TO COVID-19
NEWS BRIEFS